Advances in the management of HER2-positive advanced gastric and gastroesophageal junction cancer

Journal of Clinical Gastroenterology

Volumn 46, Issue 8, 2012, Pages 637-648

  Bang, Yung Jue ^a  

^a Seoul National University   (South Korea)

Author keywords

chemotherapy; HER2; herceptin; stomach cancer; trastuzumab

Indexed keywords

CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; LAPATINIB; OXALIPLATIN; PACLITAXEL; PERTUZUMAB; TRASTUZUMAB; TRASTUZUMAB EMTANSINE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADVANCED CANCER; ANEMIA; ANOREXIA; ASTHENIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CHILL; CONSTIPATION; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSPHAGIA; DYSPNEA; ESOPHAGUS CANCER; FATIGUE; FEBRILE NEUTROPENIA; FEVER; GENE AMPLIFICATION; GENE OVEREXPRESSION; HAND FOOT SYNDROME; HUMAN; HYPOKALEMIA; IMMUNOHISTOCHEMISTRY; KIDNEY DYSFUNCTION; LOWER ESOPHAGUS SPHINCTER CANCER; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; STOMACH CANCER; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; WEIGHT REDUCTION;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; HUMANS; RECEPTOR, ERBB-2; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84865499429     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3182557307     Document Type: Review

References (82)

1. Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 (GLOBOCAN web site). Lyon, France International Agency for Research on Cancer; 2010. Available at: http:// globocan.iarc.fr. Accessed September 22, 2011.
2. Shah MA, Kelsen DP. Gastric cancer: A primer on the epidemiology and biology of the disease and an overview of the medical management of advanced disease. J Natl Compr Canc Netw. 2010;8:437-447.
3. Cunningham SC, Kamangar F, Kim MP, et al. Survival after gastric adenocarcinoma resection: eighteen-year experience at a single institution. J Gastrointest Surg. 2010;9:718-725.
4. Howlander N, Noone AM, Krapcho M, et al. SEER cancer statistics review 1975-2008 (SEER web site). November 2010. Available at: http://seer.cancer.gov/ csr/1975-2008. Accessed September 22, 2011.
5. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J ClinOncol. 2006;24:2137-2150.
6. Ahn HS, Lee HJ, Hahn S, et al. Evaluation of the seventh American Joint Committee on Cancer/International Union Against Cancer Classification of gastric adenocarcinoma in comparison with the sixth classification. Cancer. 2010;116: 5592-5598.
7. Inoue M, Tsugane S. Epidemiology of gastric cancer in Japan. Postgrad Med J. 2005;81:419-424.
8. Murad AM, Santiago FF, Petroianu A, et al. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer. 1993;72:37-41.
9. Shimoyama S, Itouji T, Enomoto H, et al. Our experiences of best supportive care for gastric cancer patients (in Japanese with English abstract). Gan To Kagaku Ryoho. 2010;37: 259-262.
10. Kang H, Kauh JS. Chemotherapy in the treatment of metastatic gastric cancer: is there a global standard? Curr Treat Options Oncol. 2011;12:96-106.
11. Sastre J, Garcia-Saenz JA, Diaz-Rubio E. Chemotherapy for gastric cancer. World J Gastroenterol. 2006;12:204-213.
12. Wagner A.D. Unverzagt S. Grothe W. et al.Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2010;3:CD004064.
13. Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial. Lancet Oncol. 2008;9:215-221.
14. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36-46.
15. Kang YK, Kang WK, Shin DB, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: A randomised phase III noninferiority trial. Ann Oncol. 2009;20:666-673.
16. Okines AF, Norman AR,McCloud P, et al.Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol. 2009;20:1529-1534.
17. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 Study Group. J Clin Oncol. 2006;24:4991-4997.
18. Gravalos C, Jimeno A. HER2 in gastric cancer: A new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19:1523-1529.
19. Schluter B, Gerhards R, Strumberg D, et al. Combined detection of Her2/neu gene amplification and protein overexpression in effusions from patients with breast and ovarian cancer. J Cancer Res Clin Oncol. 2010;136:1389-1400.
20. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177-182.
21. Beltran GB, Yabar BA. HER2 expression in gastric cancer in Peru (in Spanish with English abstract). Rev Gastroenterol Peru. 2010;30:324-327.
22. Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008;52:797-805.
23. Im SA, Kim JW, Kim JS, et al. Clinicopathologic characteristics of patients with stage III/IV (M(0)) advanced gastric cancer, according to HER2 status assessed by immunohistochemistry and fluorescence in situ hybridization. Diagn Mol Pathol. 2011;20:94-100.
24. Tanner M, Hollmén M, Junttila TT, et al. Amplification of HER-2 in gastric carcinoma: Association with topoisomerase II alpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol. 2005;16:273-278.
25. Albarello L, Pecciarini L, Doglioni C. HER2 testing in gastric cancer. Adv Anat Pathol. 2011;18:53-59.
26. Grabsch H, Sivakumar S, Gray S, et al. HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value-conclusions from 924 cases of two independent series. Cell Oncol. 2010;32:57-65.
27. Maresch J, Schoppmann SF, Thallinger CM, et al. Her-2/neu gene amplification and over-expression in stomach and esophageal adenocarcinoma: from pathology to treatment. Crit Rev Oncol Hematol. 2011. [Epub ahead of print].
28. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med. 2007;357:39-51.
29. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
30. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659-1672.
31. Slamon D, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients: BCIRG 006 study. San Antonio Breast Cancer Symposium, 2009; San Antonio, TX, abstract 62.
32. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673-1684.
33. Boekhout AH, Beijnen JH, Schellens JH. Trastuzumab. Oncologist. 2011;16:800-810.
34. Spector N.L. Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer J Clin Oncol. 2009 5838-5847
35. Cortés-Funes H, Rivera F, Alé s I, et al. Phase II of trastuzumab and cisplatin in patients (pts) with advanced gastric cancer (AGC) with HER2/neu overexpression/amplification. J Clin Oncol. 2007;18S. Abstract 4613.
36. Nicholas G, Cripps C, Au H-J, et al. Early results of a trial of trastuzumab, cisplatin, and docetaxel (TCD) for the treatment of metastatic gastric cancer overexpressing HER-2. European Society for Medical Oncology Meeting, 2006
37. Bang Y.J. Van Cutsem E. Feyereislova A. et al. rastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastrooesophageal junction cancer (ToGA) a phase 3, open-label, randomised controlled trial Lancet. 2010;376:687-697
38. Satoh T, Leon J, Lopez RI, et al. Quality of life results from a phase III trial of trastuzumab plus chemotherapy in first-line HER2-positive advanced gastric and GE junction cancer. ASCO Gastrointestinal Cancers Symposium, 2010; Orlando, FL, abstract 7.
39. Kang Y-K, Shen L, Lichinitser M, et al. Self-rated pain assessment by patients with HER2-positive advanced gastric/GEJ cancer treated with 5-FU/capecitabine and cisplatin with or without trastuzumab: exploratory QOL analysis from the Phase III ToGA study. Gastroenterology. 2011;140:S-204.
40. Osoba D, Rodrigues G, Myles J, et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16:139-144.
41. Ohtsu A, Wang L, Lim HY, et al. Quality of life results from a phase III study of trastuzumab plus chemotherapy as first-line therapy in patients with HER2-positive advanced gastric and gastro-oesophageal junction cancer. WCGC 2010 Barcelona, Spain, poster O-0011.
42. Gelber RD, Gelman RS, Goldhirsch A. A quality-of-lifeoriented endpoint for comparing therapies. Biometrics. 1989; 45:781-795
43. Glasziou PP, Simes RJ, Gelber RD. Quality adjusted survival analysis. Stat Med. 1990;9:1259-1276.
44. Chung H.C. Bang Y.-J. Van Cutsem E. et al. Q-TWIST analysis of trastuzumab plus fluoropyrimidine/cisplatin (T-XP/FP) versus XP/FP alone as first-line therapy for advanced HER2-positive gastric cancer. J Clin Oncol. 2010;28. Abstract 4048.
45. Powell WC, Zielinski D, Ranger-Moore J, et al. Determining the HER2 status in gastric cancer: A method comparison study of two patient cohorts. ASCO Gastrointestinal Cancers Symposium, 2010; Orlando, FL, abstract 17.
46. Herceptin summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Product-Information/ human/000278/WC500074922. pdf. Accessed September 22, 2011.
47. NCCN clinical practice guidelines in oncology (NCCN guidelinest). Gastric Cancer. Version 2.2011. http://www.nccn.org/professionals/physician-gls/pdf/ gastric.pdf. Accessed September 22, 2011.
48. Herceptin prescribing information. Available at: http:// www.accessdata.fda.gov/drugsatfda-docs/label/2010/103792s5 256lbl.pdf. Accessed September 26, 2011.
49. Study of Capecitabine (Xeloda) in Combination with Trastuzumab (Herceptin) and Oxaliplatine in Patients with Resectable Gastric Cancer
50. Iqbal S, Goldman B, Fenoglio-Preiser CM, et al. Southwest Oncology Group study S0413: A phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer. Ann Oncol. 2011;22:2610-2615.
51. Tevaarwerk A.J. Kolesar J.M. Lapatinib: A small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer. Clin Ther. 2009;31:2332-2348.
52. Molina MA, Codony-Servat J, Albanell J, et al. Trastuzumab (Herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res. 2001;61:4744-4749.
53. Gril B, Palmieri D, Bronder JL, et al. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst. 2008;100:1092-1103.
54. Lin NU, Carey LA, Younger J, et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2008;26:1993-1999.
55. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355:2733-2743.
56. Amir E, Ocana A, Seruga B, et al. Lapatinib and HER2 status: results of a meta-analysis of randomized phase III trials in metastatic breast cancer. Cancer Treat Rev. 2010;36:410-415.
57. Yip AY, Tse LA, Ong EY, et al. Survival benefits from lapatinib therapy in women with HER2-overexpressing breast cancer: A systematic review. Anticancer Drugs. 2010;21:487-493.
58. LOGiC-lapatinib optimization study in ErbB2 (HER2) positive gastric cancer: A phase III global, blinded study designed to evaluate clinical endpoints and safety of chemotherapy plus lapatinib. Available at: http://clinicaltrials.gov/ct2/show/NCT00680901. Accessed September 22, 2011.
59. Hecht J, Bang Y-J, Sobrero A, et al. A phase III study of CapeOx +/lapatinib in HER2 positive locally advanced/metastatic upper gastrointestinal adenocarcinoma: interim safety results. European Society for Medical Oncology Meeting 2009; Berlin, Germany, poster 6.584.
60. Lapatinib in combination with weekly paclitaxel in patients with ErbB2 amplified advanced gastric cancer. Available at: http://clinicaltrials.gov/ct2/ show/NCT00486954. Accessed September 22, 2011.
61. Satoh T, Bang Y, Wang J, et al. Interim safety analysis from TYTAN a phase III Asian study of lapatinib in combination with paclitaxel as second-line therapy in gastric cancer. J ClinOncol. 2010;28. Abstract 4057.
62. Hughes JB, Berger C, Rodland MS, et al. Pertuzumab increases epidermal growth factor receptor down-regulation by counteracting epidermal growth factor receptor-ErbB2 heterodimerization. Mol Cancer Ther. 2009;8:1885-1892.
63. Baselga J, Gelmon KA, Verma S, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol. 2010;28:1138-1144.
64. A Study of pertuzumab in combination with trastuzumab and chemotherapy in patients with HER2-positive advanced gastric cancer. Available at: http://clinicaltrials.gov/ct2/show/NCT01461057. Accessed February 23, 2012.
65. Lewis Phillips GD, Li G, Dugger DL, et al. Targeting HER2- positive breast cancer with trastuzumab-DM1, an antibodycytotoxic drug conjugate. Cancer Res. 2008;68:9280-9290.
66. Junttila TT, Li G, Parsons K, et al. Trastuzumab-DM1 (TDM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat. 2010;128:347-356.
67. Hurvitz S, Dirix L, Kocsis J, et al. Trastuzumab emtansine (TDM1) versus trastuzumab plus docetaxel (H+T) in previouslyuntreated HER2-positive metastatic breast cancer (MBC): primary results of a randomized, multicenter, open-label phase II study (TDM4450g/BO21976). European Society for Medical Oncology Meeting, 2010 Milan, Italy, abstract 5001.
68. Perez EA, Dirix L, Kocsis J, et al. Efficacy and safety of trastuzumab-DM1 versus trastuzumab plus docetaxel in HER2-positive metastatic breast cancer patients with no prior chemotherapy for metastatic disease preliminary results of a randomized, multicenter, open-label phase 2 study. European Society for MedicalOncology Meeting, 2010; Milan, Italy, abstract LBA3.
69. Chugai (press release). Anti-cancer agent, Herceptins obtained approval for additional indication of advanced or recurrent gastric cancer overexpressing HER2, not amenable to curative resection. Available at: http://www.chugai- pharm.co. jp/hc/ss/english/news/detail/20110310150000.html. Accessed September 22, 2011.
70. Berns K, Horlings HM, Hennessy BT, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 2007;12:395-402.
71. Lu Y, Zi X, Zhao Y, et al. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst. 2001;93:1852-1857.
72. Sergina NV, Rausch M, Wang D, et al. Escape from HERfamily tyrosine kinase inhibitor therapy by the kinaseinactive HER3. Nature. 2007;445:437-441.
73. Nagata Y, Lan KH, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 2004;6:117-127.
74. Kostler WJ, Schwab B, Singer CF, et al. Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. Clin Cancer Res. 2004;10:1618-1624.
75. Zabrecky JR, Lam T, McKenzie SJ, et al. The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3. J Biol Chem. 1991;266: 1716-1720.
76. Nagy P, Friedlander E, Tanner M, et al. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptinresistant, MUC4-expressing breast cancer cell line. Cancer Res. 2005;65:473-482.
77. Price-Schiavi SA, Jepson S, Li P, et al. Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance. Int J Cancer. 2002;99:783-791.
78. Musolino A, Naldi N, Bortesi B, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neupositive metastatic breast cancer. J Clin Oncol. 2008;26: 1789-1796.
79. Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010;28:1124-1130.
80. Baselga J, Bradbury I, Eidtmann H, et al. First results of the NeoALTTO Trial (BIG 01-06/EGF 106903): A phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2-positive primary breast cancer. San Antonio Breast Cancer Symposium, 2010
81. Gianni L, Pienkowski T, Im Y-H, et al. Neoadjuvant pertuzumab (P) and trastuzumab (H) antitumor and safety analysis of a randomized phase II study (-NeoSphere-). San Antonio Breast CancerSymposium, 2010; San Antonio, TX,abstract S3-2.
82. Bang Y, Kim YW, Yang H, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer: results of the phase IIICLASSIC trial. J Clin Oncol. 2011;29. abstract LBA4002.